Boston pushes ahead with atrial flutter ablation technology
This article was originally published in Clinica
Executive Summary
Boston Scientific is close to receipt of final premarket approval (PMA) from the FDA to sell in the US its radiofrequency (RF) cardiac ablation system for treating atrial flutter - a condition that can cause heart failure and stroke. The US agency is currently reviewing the seventh and final PMA module for the system.